FrancophonIA/ELRC3.0 huggingface dataset:
English: Infants from 6 months of age, children, adolescents and adults One injection.
Croatian: Dojenčad u dobi od 6 mjeseci, djeca, adolescenti i odrasli Jedna injekcija.
English: Nimenrix MenC-CRM vaccine 116
Croatian: MenC-CRM cjepivo 116
English: Study MenACWYTT-035 (18-55 years)
Croatian: Ispitivanje MenACWYTT-035 (18-55 godina)
English: Infants from 6 months of age, children, adolescents and adults: a single 0.5 mL dose should be administered.
Croatian: Dojenčad u dobi od 6 mjeseci, djeca, adolescenti i odrasli: treba primijeniti jednokratnu dozu od 0,5 ml.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING 1 VIAL AND 1 AMPOULE
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU 1 BOČICA I 1 AMPULA
English: Data from MenACWY-TT-083 support the extrapolation of the immunogenicity data and posology to infants from 12 weeks to less than 6 months of age.
Croatian: Podaci iz ispitivanja MenACWY-TT-083 podržavaju ekstrapolaciju podataka o imunogenosti i doziranju za dojenčad u dobi od 12 tjedana do manje od 6 mjeseci.
English: In individuals from 1 year of age, the recommended injection site is the anterolateral aspect of the thigh or the deltoid muscle (see sections 4.4 and 4.5).
Croatian: U pojedinaca u dobi od godine dana pa nadalje, preporučeno mjesto injekcije je anterolateralni dio bedra ili deltoidni mišić (vidjeti dijelove 4.4 i 4.5).
English: Nimenrix is available in packs of 1, 10 or 100.
Croatian: Nimenrix je dostupan u pakiranjima s 1, 10 ili 100 doza cjepiva.
English: Study MenACWYTT-036 (11-17 years)
Croatian: Ispitivanje MenACWYTT-036 (11-17 godina)
English: België/Belgique/Belgien Luxembourg/Luxemburg
Croatian: België/Belgique/Belgien Luxembourg/Luxemburg Pfizer S.A./ N.V.
English: There was no impact of co-administration on immune responses to Nimenrix or the tetanus or diphtheria antigens included in Tdap.
Croatian: Istodobna primjena nije imala utjecaja na imunološki odgovor na Nimenrix ili antigene tetanusa ili difterije uključene u Tdap.
English: A protective immune response may not be elicited in all vaccinees.
Croatian: Zaštitni imunološki odgovor možda se neće postići kod svih cijepljenika.
English: Nimenrix may be given to adults, adolescents, children and infants over the age of 6 weeks.
Croatian: Nimenrix se može dati odraslima, adolescentima, djeci i dojenčadi starijoj od 6 tjedana.
English: Nimenrix should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the foetus.
Croatian: Nimenrix u trudnoći treba davati samo u slučajevima kada postoji jasna potreba i kada moguća korist nadilazi moguće rizike za plod.
English: If Nimenrix is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.
Croatian: Ako se Nimenrix treba dati istodobno s nekim drugim cjepivom koje se daje injekcijom, uvijek ih treba davati na različita mjesta.
English: It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate immune response may not be elicited.
Croatian: Može se očekivati da se u bolesnika koji primaju imunosupresivnu terapiju ili u bolesnika s imunodeficijencijom neće postići odgovarajući imunološki odgovor.
English: Timepoint (months)
Croatian: Vrem. točka (mjeseci)
English: The safety and antibody persistence data up to year 5 and the data on co-administration of MenACWY-TT with Prevenar 13 will be provided in sequential study reports at 1, 3 and 5 years after vaccination.
Croatian: Podaci o sigurnosti i postojanosti protutijela do 5 godina i podaci o istodobnoj primjeni MenACWY-TT s Prevenarom 13 bit će dostupni u serijskim izvješćima o ispitivanju 1, 3 i 5 godina nakon cijepljenja.
English: Nimenrix should only be used during breast-feeding when the possible advantages outweigh the potential risks.
Croatian: Nimenrix tijekom dojenja treba davati samo u slučajevima kada moguća korist nadilazi moguće rizike.
English: It may be expected that in patients receiving immunosuppressive treatment, an adequate response may not be elicited.
Croatian: Može se očekivati da se u bolesnika koji primaju imunosupresivnu terapiju neće postići adekvatan imunološki odgovor.
English: Insomnia Crying
Croatian: Nesanica Plačljivost
English: • bruising (haematoma) where the injection is given
Croatian: • modrica (hematom) na mjestu davanja injekcije
English: • reactions where the injection is given such as itching, a feeling of warmth or numbness or a hard lump.
Croatian: • reakcije na mjestu davanja injekcije poput svrbeža, osjećaja topline, utrnulosti ili tvrde kvržice.
English: Immunogenicity in children aged 2-10 years
Croatian: Imunogenost u djece u dobi od 2 do 10 godina
English: Holding the syringe barrel in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise.
Croatian: Držeći cijev štrcaljke u jednoj ruci (izbjegavajte držati klip štrcaljke), odvijte zatvarač štrcaljke okrećući ga suprotno smjeru kazaljke na satu.
English: Pfizer Tél +33 1 58 07 34 40
Croatian: Tél +33 1 58 07 34 40
English: Nimenrix should under no circumstances be administered intravascularly, intradermally or subcutaneously.
Croatian: Nimenrix se ni pod kojim okolnostima ne smije primijeniti intravaskularno, intradermalno ili supkutano.
English: *tested at GSK laboratories
Croatian: * ispitano u laboratorijima tvrtke GSK
English: No studies on the effects of Nimenrix on the ability to drive and use machines have been performed.
Croatian: Nisu provedena ispitivanja o utjecaju cjepiva Nimenrix na sposobnost upravljanja vozilima i rada sa strojevima.
English: Vaccination with Nimenrix should be postponed in subjects suffering from an acute severe febrile illness.
Croatian: Cijepljenje cjepivom Nimenrix treba odgoditi u osoba s teškom akutnom bolešću praćenom vrućicom.
English: This total included 3,079 toddlers (12 months to 23 months), 909 children between 2 and 5 years of age, 990 children between 6 and 10 years of age, 2,317 adolescents (11 to 17 years) and 2,326 adults (18 to 55 years).
Croatian: Ukupno je uključeno 3079 male djece (u dobi od 12 do 23 mjeseca), 909 djece u dobi od 2 do 5 godina, 990 djece u dobi od 6 do 10 godina, 2317 adolescenata (u dobi od 11 do 17 godina) i 2326 odraslih osoba (u dobi od 18 do 55 godina).
English: Meningococcal Group rSBA*
Croatian: Meningo kok serogrup rSBA*
English: Although an increase of the anti-tetanus toxoid (TT) antibody concentrations was observed following vaccination with Nimenrix, Nimenrix does not substitute for tetanus immunisation.
Croatian: Nimenrix uočen porast koncentracije protutijela protiv toksoida tetanusa (TT), Nimenrix ne zamjenjuje imunizaciju za tetanus.
English: Nimenrix was demonstrated to be immunologically non-inferior to the ACWY-PS vaccine in terms of vaccine response as defined above (Table 12).
Croatian: Pokazano je da Nimenrix nije imunološki inferioran u odnosu na cjepivo ACWY-PS u pogledu odgovora na cjepivo kako je definirano iznad (Tablica 12).
English: • This vaccine has been prescribed for you or your child. Do not pass it on to others.
Croatian: • Ovo je cjepivo propisano Vama ili Vašem djetetu.
English: After the addition of the solvent to the powder, the mixture should be well shaken until the powder is completely dissolved in the solvent.
Croatian: Nakon dodavanja otapala prašku, mješavinu treba dobro protresti sve dok se prašak u potpunosti ne otopi u otapalu.
English: Nimenrix elicited a bactericidal antibody response against the four meningococcal groups.
Croatian: Nimenrix je izazvao baktericidni odgovor protutijela protiv četiri skupine meningokoka.
English: VR: vaccine response defined as the proportion of subjects with:
Croatian: VR: odgovor na cjepivo (vaccine response) definiran kao omjer ispitanika s:
English: *rSBA testing performed at PHE laboratories in UK.
Croatian: * ispitivanje rSBA provedeno je u PHE laboratorijima u Ujedinjenom Kraljevstvu.
English: Immunisation should be carried out by intramuscular injection only.
Croatian: Cijepljenje se smije provesti samo intramuskularnom injekcijom.
English: Table 1 shows the adverse reactions reported from the studies in subjects aged from 6 weeks up to 55 years of age and post-marketing experience.
Croatian: Tablica 1 prikazuje nuspojave prijavljene iz ispitivanja ispitanika u dobi od 6 tjedana do 55 godina i iskustvo nakon stavljanja lijeka u promet.
English: Pfizer Limited Tel: +44 (0) 1304 616161
Croatian: United Kingdom Pfizer Limited Tel: +44 (0) 1304 616161
English: A new needle should be used to administer the vaccine.
Croatian: Za primjenu cjepiva treba upotrijebiti novu iglu.
English: Study to evaluate immediate and longer term antibody titres elicited by one or two doses of Nimenrix administered in children aged 12-23 months.
Croatian: Ispitivanje za procjenu neposrednih i dugoročnih titara protutijela potaknutih nakon jedne ili dvije doze cjepiva Nimenrix danog djeci u dobi od 12 do 23 mjeseca.
English: In clinical studies MenACWY-TT-039 and MenACWY-TT-040 a single dose of Nimenrix elicited rSBA responses against the four meningococcal groups, with a response against group C that was comparable to the one elicited by the licensed MenC-CRM vaccine in terms of percentages with rSBA
Croatian: U kliničkim ispitivanjima MenACWY-TT-039 i MenACWY-TT-040, jednokratna doza cjepiva Nimenrix potakla je rSBA odgovore protiv četiri meningokokne grupe, s odgovorom protiv grupe C koji se može usporediti s onim koje je postiglo odobreno cjepivo MenC-CRM u smislu postotaka s rSBA titrima ≥8 (Tablica 4).
English: Powder for Nimenrix MenACWY Conjugate IM
Croatian: Prašak za Nimenrix MenACWY konjugat i.m.
English: Nervous system disorders
Croatian: Poremećaji živčanog sustava vrlo često
English: The mixture should be well shaken until the powder is completely dissolved in the solvent.
Croatian: Mješavinu treba dobro protresti sve dok se prašak u potpunosti ne otopi u otapalu.
English: The following side effects may happen with this medicine:
Croatian: S ovim cjepivom može doći do sljedećih nuspojava:
English: Therefore tell the doctor or nurse if you or your child fainted with a previous injection.
Croatian: Obavijestite stoga liječnika ili medicinsku sestru ako je Vaše dijete izgubilo svijest prilikom primanja prethodne injekcije.
English: Do not administer intravascularly, intradermally or subcutaneously.
Croatian: Lijek nemojte primijeniti intravaskularno, intradermalno ili supkutano.
English: Immunogenicity in infants
Croatian: Imunogenost u dojenčadi
English: Table 1 Tabulated summary of adverse reactions by system organ class System Organ Class
Croatian: Tablica 1 Tablični prikaz nuspojava po klasifikaciji organskih sustava Klasifikacija organskih sustava
English: What Nimenrix is and what it is used for What Nimenrix is and what it is used for
Croatian: Što je Nimenrix i za što se koristi
English: • swelling, pain and redness where the injection is given.
Croatian: • natečenost, bol i crvenilo na mjestu davanja injekcije.
English: What Nimenrix is and what it is used for What you need to know before you receive Nimenrix How Nimenrix is given
Croatian: Što je Nimenrix i za što se koristi Što morate znati prije nego počnete primjenjivati Nimenrix Kako primjenjivati Nimenrix
English: In Study Men ACWY-TT-104 the immune response following one or two doses of Nimenrix given 2 months apart was evaluated one month after the last vaccination.
Croatian: U Men ACWY-TT-104 ispitivanju imunološki odgovor nakon jedne ili dvije doze cjepiva Nimenrix dane u razmaku od 2 mjeseca, procijenjen je jedan mjesec nakon zadnjeg cijepljenja.
English: The following information is intended for healthcare professionals only: The vaccine is for intramuscular use only.
Croatian: Sljedeće informacije namijenjene su samo zdravstvenim radnicima:
English: Infants from 6 weeks to less than 6 months of age: two doses, each of 0.5 ml, should be administered with an interval of 2 months between doses.
Croatian: Dojenčad u dobi od 6 tjedana do manje od 6 mjeseci: dvije doze, svaka od 0,5 ml, trebaju se primijeniti uz interval od 2 mjeseca između dviju doza.
English: Break the top of the ampoule, draw up the solvent with a syringe and add the solvent to the powder.
Croatian: Uklonite vrh ampule, špricom izvucite otapalo i dodajte otapalo prašku.
English: Nimenrix is available in packs of 1 or 10 with or without needles.
Croatian: Nimenrix je dostupan u pakiranjima s 1 ili 10 doza cjepiva, s ili bez igala.
English: Very common (these may occur with more than 1 in 10 doses of the vaccine):
Croatian: Vrlo česte (mogu se javiti u više od 1 na 10 doza cjepiva):
English: • generally feeling unwell
Croatian: • općenito loše osjećanje
English: Diarrhoea Vomiting Nausea*
Croatian: Proljev Povraćanje Mučnina*
English: In the 6-12 weeks and in the 12-14 months age groups who received 2 doses of Nimenrix given 2 months apart, the first and second doses were associated with similar local and systemic reactogenicity.
Croatian: U dobnim skupinama od 6. do 12. tjedna i od 12 do 14 mjeseci koje su primile 2 doze cjepiva Nimenrix dane u razmaku od 2 mjeseca, prva i druga doza povezane su sa sličnom lokalnom i sistemskom reaktogenošću.
English: • received your dose more than approximately one year ago and could be at risk of infection caused by Neisseria meningitidis type A
Croatian: • primili svoju dozu prije više od godine dana i mogli biste biti u opasnosti od infekcije koju uzrokuje
English: The local and general adverse reaction profile of a booster dose of Nimenrix given to subjects from 12 months through 30 years of age after primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines, was similar to the local and general adverse reaction profile observed after primary vaccination with Nimenrix, except for gastrointestinal symptoms (including diarrhoea, vomiting, and nausea), which were very common among subjects 6 years of age and older.
Croatian: Profil lokalnih i općih nuspojava docjepljivanja cjepivom Nimenrix u ispitanika u dobi od 12 mjeseci do 30 godina nakon primarnog cijepljenja cjepivom Nimenrix ili drugim konjugiranim ili nekonjugiranim polisaharidnim meningokoknim cjepivima, bio je sličan profilu lokalnih i općih nuspojava uočenih nakon primarnog cijepljenja cjepivom Nimenrix, osim za gastrointestinalne simptome (uključujući proljev, povraćanje i mučninu), koji su bili vrlo česti među ispitanicima u dobi od 6 i više godina.
English: After a booster dose, the hSBA titres to all four serogroups were comparable between the two dosing schedules.
Croatian: Nakon docjepljivanja hSBA titri za sve četiri serogroupe mogli su se usporediti između dvije primjene lijeka.
English: 1conjugated to tetanus toxoid carrier protein
Croatian: 5 mikrograma konjugirano na tetanusni toksoid proteinski nosač
English: EU/1/12/767/001 - pack of 1 without needle EU/1/12/767/002 - pack of 10 without needle EU/1/12/767/003 - pack of 1 with 2 needles EU/1/12/767/004 - pack of 10 with 20 needles
Croatian: EU/1/12/767/001 - pakiranje s 1 kom bez igle EU/1/12/767/002 - pakiranje od 10 kom bez igle EU/1/12/767/003 - pakiranje s 1 kom i 2 igle EU/1/12/767/004 - pakiranje od 10 kom i 20 igala
English: Nimenrix elicited bactericidal responses against all four groups that were similar in terms of % with rSBA titre ≥8 and GMT after one or two doses (Table 6).
Croatian: Nimenrix je potakao baktericidne odgovore protiv sve četiri grupe koje su bile slične u smislu % s rSBA titrom ≥8 i GMT nakon jedne ili dvije doze (Tablica 6).
English: In study MenACWY-TT-104, serum bactericidal activity was also measured using hSBA as a secondary endpoint.
Croatian: U ispitivanju MenACWY-TT-104, serumska baktericidna aktivnost također je mjerena pomoću hSBA kao sekundarna mjera ishoda.
English: Whenever possible, Nimenrix and a TT containing vaccine, such as DTaP-HBV-IPV/Hib vaccine, should be co-administered or Nimenrix should be administered at least one month before the TT containing vaccine.
Croatian: Kad god je moguće, Nimenrix i cjepivo koje sadrži TT, poput cjepiva DTaP-HBV-IPV/Hib, treba dati istodobno, ili Nimenrix treba dati najmanje jedan mjesec prije cjepiva koje sadrži TT.
English: Persons with familial complement deficiencies (for example, C5 or C3 deficiencies) and persons receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis groups A, C, W-135 and Y, even if they develop antibodies following vaccination with Nimenrix.
Croatian: Kod osoba s nasljednim manjkom komplementa (na primjer, manjak C5 ili C3) i osoba koje primaju terapije koje inhibiraju aktivaciju terminalne komponente komplementa (na primjer, ekulizumab) postoji povećan rizik od invazivne bolesti uzrokovane Neisseria meningitidis grupama A, C, W-135 i Y, čak i ako razviju protutijela nakon cijepljenja Nimenrixom.
English: 10 x 1 dose (0.5 ml)
Croatian: 10 x 1 doza (0,5 ml)
English: A single primary dose administered at 6 months of age elicited robust rSBA responses to groups A, C, W-135 and Y, as measured by the percentage of subjects with rSBA titres ≥8, that were comparable to responses after the last dose of a three-dose primary series.
Croatian: Jednokratna primarna doza primijenjena u dobi od 6 mjeseci izazvala je robustne rSBA odgovore na grupe A, C, W-135 i Y, izmjerene postotkom ispitanika s rSBA titrima ≥ 8, koji su se mogli usporediti s odgovorima nakon zadnje doze primarne serije od tri doze.
English: Bactericidal antibody responses in infants 6 months of age measured one month after a single primary dose, prior to a booster dose, and one month after a booster dose are presented in Table 3.
Croatian: Odgovori baktericidnih protutijela u dojenčadi u dobi od 6 mjeseci, izmjereni mjesec dana nakon primjene jednokratne primarne doze, prije docjepljivanja i mjesec dana nakon docjepljivanja, prikazani su u tablici 3.
English: Immune response in infants aged 6 months to less than 12 months A single dose administered at 6 months was associated with lower human complement serum bactericidal assay (hSBA) titres to groups W-135 and Y compared with three doses administered at 2, 4, and 6 months (see section 5.1).
Croatian: Imunološki odgovor u dojenčadi u dobi od 6 mjeseci do manje od 12 mjeseci Primjena jednokratne doze u dobi od 6 mjeseci bila je povezana s nižim titrima baktericidnih protutijela u serumu mjerenih s humanim komplementom (hSBA) za grupe W-135 i Y u usporedbi s primjenom tri doze u dobi od 2, 4 i 6 mjeseci (vidjeti dio 5.1).
English: Effect of Nimenrix on anti-tetanus antibody concentrations
Croatian: Učinak cjepiva Nimenrix na koncentracije protutijela protiv tetanusa
English: After reconstitution, 1 dose (0.5 ml) contains 5 micrograms of Neisseria meningitidis group A, C, W135 and Y polysaccharides.
Croatian: Nakon rekonstitucije, 1 doza (0,5 ml) cjepiva sadrži 5 mikrograma polisaharida Neisseria meningitidis grupe A, C, W-135 i Y.
English: Persistence of immunogenicity was analysed using the year 5 ATP cohort.
Croatian: Postojanost imunogenosti analizirana je korištenjem ATP-kohorte u petoj godini.
English: Nimenrix 1 dose
Croatian: Nimenrix 1 doza
English: In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus bivalent [Type 16 and 18] vaccine, recombinant (HPV2).
Croatian: U osoba u dobi od 9 do 25 godina Nimenrix se može dati istodobno s dvovalentnim [protiv tipova 16 i 18], rekombinantnim cjepivom protiv humanog papilomavirusa (HPV2).
English: ACWY-PS vaccine
Croatian: ACWY-PS cjepivo
English: Add the solvent to the powder.
Croatian: Dodajte otapalo prašku.
English: Pregnancy There is limited experience with use of Nimenrix in pregnant women.
Croatian: Podaci o primjeni cjepiva Nimenrix u trudnica su ograničeni.
English: Infants from 6 weeks to less than 12 months of age: One booster dose at 12 months of age, at least 2 months after the last dose of Nimenrix.
Croatian: Dojenčad u dobi od 6 tjedana do manje od 12 mjeseci: Jedno docjepljivanje u dobi od 12 mjeseci, najmanje 2 mjeseca nakon zadnje doze cjepiva Nimenrix.
English: • The active substances are: - After reconstitution, 1 dose (0.5 ml) contains: Neisseria meningitidis group A polysaccharide1
Croatian: • Djelatne tvari su: - Nakon pripreme, 1 doza (0,5 ml) cjepiva sadrži: polisaharid Neisseria meningitidis grupe
English: After completion of the primary immunisation course in infants 6 weeks to less than 12 months of age, a booster dose should be given at 12 months of age with an interval of at least 2 months after the last Nimenrix vaccination (see section 5.1).
Croatian: Nakon završetka ciklusa primarne imunizacije u dojenčadi u dobi od 6 tjedana do manje od 12 mjeseci potrebno je primijeniti docjepljivanje u dobi od 12 mjeseci uz interval od najmanje 2 mjeseca nakon zadnjeg cijepljenja cjepivom Nimenrix (vidjeti dio 5.1).
English: In infants, Nimenrix can be given concomitantly with combined DTaP-HBV-IPV/Hib vaccines and with 10-valent pneumococcal conjugate vaccine.
Croatian: U dojenčadi Nimenrix se može dati istodobno s kombiniranim cjepivima DTaP-HBV-IPV/Hib i s 10valentnim konjugiranim pneumokoknim cjepivom.
English: Nimenrix elicited bactericidal responses against groups W-135 and Y that were higher in terms of % with hSBA titre ≥8 when two doses were given compared with one.
Croatian: Nimenrix je potakao baktericidne odgovore protiv grupa W-135 i Y koji su bili viši u smislu % s hSBA titrom ≥8 kada su dane dvije doze u odnosu na davanje jedne doze.
English: • stomach and digestion problems such as diarrhoea, vomiting and nausea
Croatian: • problemi sa želucem i probavom poput proljeva, povraćanja i mučnine
English: Powder in a vial (type I glass) with a stopper (butyl rubber) and solvent in an ampoule (type I glass).
Croatian: Prašak u bočici (staklo tip I) sa čepom (butil) i otapalo u ampuli (staklo tip I).
English: The reconstituted vaccine is a clear colourless solution.
Croatian: Pripremljeno cjepivo je bistra bezbojna otopina.
English: Pfizer ApS Tlf: + 45 44 201 100
Croatian: Danmark Pfizer ApS Tlf: +45 44 201 100
English: The response against group C was non-inferior to the one elicited by licensed MenC-CRM and MenC-TT vaccines in terms of percentages with rSBA titres ≥8 at one month after the second dose.
Croatian: Odgovor protiv skupine C nije bio niži od onog izazvanog odobrenim MenC-CRM i MenC-TT cjepivima u smislu postotaka rSBA titara≥8 u prvom mjesecu nakon druge doze.
English: DTaP-HBV-IPV/Hib and a 10-valent pneumococcal vaccine were co-administered.
Croatian: DTaP-HBV-IPV/Hib i 10-valentno pneumokokno cjepivo primijenjeni su istodobno.
English: Immune responses in toddlers aged 12-14 months
Croatian: Imunološki odgovor u male djece u dobi od 12 do 14 mjeseci
English: The percentage of subjects with rSBA titres (measured at GSK's laboratories) ≥ 128 before vaccination ranged from 45% (group C) to 62% (group Y).
Croatian: Postotak ispitanika s titrima rSBA (mjereno u GSK-ovim laboratorijima) ≥128 prije cijepljenja bio je u rasponu od 45% (grupa C) do 62% (grupa Y).
English: Table 11: 1 month post-vaccination and 1 year persistence data (hSBA*) in children 6-10 years of age
Croatian: Tablica 11: Podaci o postojanosti jedan mjesec i jednu godinu nakon cijepljenja (hSBA*) u djece u dobi od 6 do 10 godina
English: To attach the needle to the syringe, refer to the below picture.
Croatian: Da biste pričvrstili iglu na štrcaljku, pogledajte sliku ispod.
English: Hypoaesthesia Dizziness
Croatian: Hipoestezija Omaglica
English: If Nimenrix is co-administered with other vaccines, different injection sites should be used.
Croatian: Ako se Nimenrix daje zajedno s drugim cjepivima, treba ga dati u drugo mjesto injiciranja.
English: Two clinical studies have been conducted in infants, MenACWY-TT-083 and MenACWY-TT-087.
Croatian: Dva klinička ispitivanja, MenACWY-TT-083 i MenACWY-TT-087, provedena su na dojenčadi.
English: Trometamol Sodium chloride Water for injections
Croatian: Pomoćne tvari: saharoza trometamol natrijev klorid voda za injekcije